You are here

Article Text

Article menu

Download PDFPDF

Review
Roadmap for biomarkers of cancer therapy cardiotoxicity
  1. Anthony F Yu1,
  2. Bonnie Ky2,3
  1. 1Department of Medicine, Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  2. 2Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
  3. 3Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
  1. Correspondence to Dr Bonnie Ky, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Division of Cardiovascular Medicine, Smilow Center for Translational Research, 3400 Civic Center Boulevard, 11-105, Philadelphia, PA 19104, USA; Bonnie.ky{at}uphs.upenn.edu

Abstract

Contemporary cancer treatment uses multiple modalities such as chemotherapy, targeted therapy and radiotherapy. These therapies, often used in combination, are associated with an increased risk of cardiotoxicity, specifically cardiomyopathy and heart failure. Cardiologists and oncologists are faced with the challenge of maximising the clinical benefit from cancer therapy while minimising the risk of early and late-onset cardiotoxicity. The current paradigm for cardiotoxicity detection and management relies primarily upon the assessment of left ventricular ejection fraction (LVEF). However, LVEF alone is limited in both diagnostic and prognostic ability. There is growing enthusiasm over the identification of newer biomarkers of cardiotoxicity that can detect cardiac injury at earlier stages of disease and could be used as an adjunctive prognostic measure to routine LVEF assessment. Thus, imaging and circulating biomarkers are currently under active investigation for use throughout the continuum of cancer care—for risk stratification of cardiotoxicity prior to treatment, detection of early cardiotoxicity during treatment and diagnosis of late cardiotoxicity in survivorship. Myocardial strain, cardiac troponin and brain natriuretic peptide are the most prominent biomarkers currently being studied, although data on novel circulating biomarkers are emerging.

https://doi.org/10.1136/heartjnl-2015-307894

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    Cardiotoxicity is a well-recognised adverse effect of many commonly used cancer therapies. The clinical manifestations of cardiotoxicity are broad and can include heart failure, cardiomyopathy, arrhythmia, ischaemia, valvular heart disease, pericardial disease, hypertension or thrombosis. While the adverse cardiovascular effects of traditional therapies such as anthracyclines and radiation therapy have been described since the 1970s,1 the use of newer therapies that exert ‘off-target’ effects has resulted in increased incidence of unanticipated cardiotoxicity.2 As cancer outcomes continue to improve, cardiovascular disease is emerging as a major cause of morbidity and mortality among survivors.3

    The inability to predict or prevent cardiotoxicity during and after cancer therapy represents a major challenge within the field of cardio-oncology.4 As such, there is a need to develop methods for personalised risk assessment. These strategies would help to inform clinical decisions that balance the therapeutic benefit of cancer therapy with cardiotoxicity risk, and identify high-risk patients who warrant close cardiac surveillance or institution of cardioprotective strategies (figure 1).

    Figure 1
    Figure 1

    Biomarkers for risk stratification, surveillance and management of cardiotoxicity. During cancer treatment, progression from the presence of baseline risk factors to the development of overt cardiotoxicity can occur throughout the continuum of cancer treatment, from the time of cancer diagnosis to cancer survivorship. Use of imaging and circulating biomarkers may help to determine baseline risk of cardiotoxicity and identify patients that could benefit from intensive cardiac monitoring or cardioprotective strategies. Early detection of subclinical cardiotoxicity may provide an opportunity to intervene earlier in the course of disease. After the development of cardiotoxicity, biomarkers may provide important prognostic information and guide cardiotoxicity treatment. Further investigation is needed to determine the optimal timing and follow-up of biomarker testing. 2D, two dimensional; 3D, three dimensional.

    As cardiomyopathy and heart failure are some of the most common and most devastating clinical manifestations of cardiotoxicity, they are the focus of this review. Heart failure and cardiomyopathy can occur at variable time intervals, classified by some investigators as follows: acute (during therapy), early progressive (within 1 year of therapy) and late progressive (greater than 1 year of therapy).5 For both early and late cardiomyopathy and heart failure, assessment of left ventricular ejection fraction (LVEF) has been the most common method used to monitor and diagnose these adverse sequelae. However, there is significant heterogeneity in the diagnostic criteria for cardiotoxicity according to LVEF as reported in the literature, resulting in difficulty comparing and harmonising findings across studies. Furthermore, LVEF as a prognostic and diagnostic tool has several limitations, including interobserver and intraobserver variability and a lack of sensitivity to detect early subclinical changes.6

    There is considerable enthusiasm in the potential role that alternative biomarkers can have in identifying vulnerable patients in the preclinical stage of cardiotoxicity, improving diagnostic accuracy and in providing insight into prognosis once cardiotoxicity occurs. In this review, we will briefly summarise the current data on imaging and circulating biomarkers prior to, during and after cancer therapy for early detection and prognosis of cardiotoxicity. We also propose future directions in the field with the ultimate goal of improving cardiovascular outcomes in cancer survivors.

    Biomarkers for risk stratification of cardiotoxicity prior to therapy

    Current data on the utility of baseline biomarker assessment for risk stratification of cardiotoxicity are limited. Echocardiography is the most common cardiac assessment performed at baseline in patients prior to the administration of cardiotoxic therapy.7 Some of the advantages of this imaging modality include its widespread availability, absence of radiation exposure and ease of use.

    Two studies in breast cancer have shown that baseline LVEF, as an ‘imaging biomarker’, holds some predictive value in defining the risk of subsequent heart failure. In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31, a randomised phase III adjuvant trial of trastuzumab in 1830 patients with HER2-positive breast cancer, borderline low LVEF (50%–54%) at baseline was strongly associated with heart failure (HR 6.72, 95% CI 2.67 to 16.92, p<0.001).8 In a regression analysis, baseline LVEF and age were used to develop a cardiac risk score: [(7+(0.4×age in years)−(0.1×baseline LVEF)]×100/4.76, which was proposed as a means to predict the probability of a cardiac event (ie, cardiac death or heart failure). Similarly, in the Herceptin Adjuvant (HERA) trial, a lower baseline LVEF was reported to be a risk factor for a cardiac end point including cardiac death, severe heart failure, or significant LVEF decline (≥10% to less than 50%).9

    A major limitation of baseline echocardiography for risk prediction of cardiotoxicity is in its limited negative predictive value. It has been recognised that patients with a normal baseline LVEF will go on to develop subsequent cardiomyopathy and heart failure, and suffer from adverse cardiovascular events.6 For example, although a borderline low LVEF was strongly associated with heart failure in NSABP B-31, heart failure was also reported in 2.1% and 4.2% of patients with a baseline LVEF of ≥65% and 55%–64%, respectively.8 Another disadvantage of echocardiography is the variability of LVEF, in part attributed to interobserver and intraobserver variability and limitations in image quality. While baseline LVEF assessment will remain an important screening tool to exclude patients with pre-existing cardiovascular disease from receiving cardiotoxic therapy, more sensitive metrics will be needed to accurately detect subclinical dysfunction and predict the risk of subsequent disease (table 1).

    View this table:
    Table 1

    Advantages and disadvantages of imaging and circulating biomarkers

    Biomarkers for the detection of early cardiotoxicity during cancer therapy

    Imaging biomarkers

    During cardiotoxic therapy, echocardiography remains the most commonly used modality.7 Newer techniques using contrast echocardiography and three-dimensional (3D) echocardiography have resulted in significant improvement in the accuracy of LVEF assessment. This was demonstrated in a small study of 50 patients with breast cancer undergoing serial LVEF assessments, in which 3D-echocardiography was feasible and reproducible for assessing changes in LV volumes and LVEF compared with the gold standard cardiac MRI.10 Similarly, in a study by Thavendiranathan et al,7 non-contrast 3D-echocardiography was the most reproducible technique for LVEF assessment capable of detecting smaller changes in LVEF (∼5%). However, a decrease in LVEF is still considered to be a late manifestation of cancer therapy-associated cardiotoxicity and may reflect the presence of irreversible myocardial damage. Thus, efforts have focused on identifying more sensitive measures of LV systolic function.

    Newer techniques of assessing myocardial deformation (eg, strain, strain rate, twist and torsion) have been proposed as more sensitive tools for the detection of subclinical LV systolic dysfunction. Strain was initially measured with tissue Doppler imaging (TDI), but this technique is limited by the angle dependence inherent to TDI as well as the inability to differentiate translational motion or tethering effects from adjacent segments. Speckle tracking echocardiography (STE), which uses an image-processing algorithm to track patterns of ‘speckles’ or natural echocardiographic signals, has replaced TDI as the preferred method for multidirectional strain measurement (ie, longitudinal, radial and circumferential).

    Global longitudinal strain (GLS) has thus far been identified as the most robust strain parameter for cardiotoxicity monitoring during therapy. Several studies have shown that GLS determined by STE can detect myocardial injury before the development of an overt decline in LVEF. In a prospective study by Sawaya et al,11 STE was performed at baseline (before anthracycline chemotherapy), after the completion of anthracyclines and every 3 months over 15 months in 81 patients treated with adjuvant anthracycline-based chemotherapy plus trastuzumab. A GLS of <19% (derived as an average of the apical 4-chamber and 2-chamber views, excluding the apex) after the completion of anthracycline treatment was predictive of later development of cardiotoxicity (positive predictive value 53%, negative predictive value 87%), defined as a symptomatic reduction of LVEF ≥5% to <55% or an asymptomatic reduction of LVEF ≤10% to <55%. Although reductions were also observed in radial and circumferential strain, these parameters were not associated with subsequent heart failure. A similar study by Negishi et al12 of 81 women receiving adjuvant trastuzumab also demonstrated that GLS was an independent early predictor of later declines in LVEF. STE was performed at baseline and at 6 and 12 months, and an 11% reduction in GLS was the strongest predictor of cardiotoxicity, defined by a reduction of LVEF ≥10%. Findings from this study also suggest that the change in GLS from baseline is predictive of cardiotoxicity. These two studies have informed the development of the expert consensus for multimodality imaging in patients with cancer by the American Society of Echocardiography (ASE), which recommends the use of GLS in the assessment of cardiac function in patients with cancer, and suggests that a change in GLS can be used to detect early subclinical changes in LV systolic function.13

    Cardiac MRI, which is the gold standard for the measurement of ventricular volumes and function, has the unique ability to characterise myocardial tissue and potentially identify early signs of cardiac injury.14 Two techniques have been investigated for the detection of cardiotoxicity. Late gadolinium enhancement (LGE) is an established imaging method for the detection of focal myocardial fibrosis and scar, but has shown poor diagnostic and prognostic value in cancer survivors.15 Alternatively, estimation of extracellular volume fraction using T1 mapping is able to identify diffuse patterns of myocardial injury likely to be associated with cancer therapy, but requires further investigation.16

    Practice guidelines have been published by professional organisations including the National Comprehensive Cancer Network (NCCN),17 European Society of Medical Oncology (ESMO),18 and ASE13 that provide recommendations for cardiac imaging during cardiotoxic cancer therapy. However, evidence supporting the effectiveness of cardiac imaging to reduce cardiotoxicity remains limited and current recommendations are largely based upon expert opinion and cardiac monitoring algorithms used in the context of large clinical trials. Future studies are needed to determine the most appropriate modality of cardiac imaging, the optimal frequency and threshold of testing, and how interventions based on cardiac imaging impact cancer or cardiac-related outcomes (table 1).

    Circulating biomarkers

    Circulating blood-based biomarkers are actively under investigation as possible alternatives to cardiac imaging for the diagnosis and prediction of cardiotoxicity (table 1). Widely established biomarkers have the advantage of being reproducible measures that are often readily attainable. In addition, circulating biomarkers provide biologic insight and may inform the underlying mechanism of cardiotoxicity.

    Troponin

    Cardiac troponins are markers of myocardial injury and play an important role in the diagnosis of acute coronary syndromes.19 In cardio-oncology, troponin has been the most widely studied biomarker. In a study by Cardinale et al of 204 patients receiving high-dose chemotherapy, troponin I (TnI) elevation was observed in 32% of patients and was predictive of subsequent LVEF decline.20 A follow-up study was performed by the same group in 703 patients treated with high-dose chemotherapy. These patients underwent serial TnI monitoring at multiple time-points with each cycle of treatment (immediately after, 12, 24, 36 and 72 h after each cycle) and 1 month after chemotherapy.21 The pattern of TnI elevation identified patients at various levels of risk for cardiotoxicity. Specifically, the highest cardiotoxicity event rate was observed among patients with early (within 72 h) TnI elevation (≥0.08 ng/mL) that persisted at 1 month after treatment. A similar study performed in patients treated with trastuzumab demonstrated that an elevated TnI was associated with a lack of LVEF recovery despite heart failure therapy.22

    New high-sensitivity troponin assays are currently available that provide superior diagnostic accuracy for acute coronary syndromes,19 and have been under investigation for the early detection of cardiotoxicity. A study by Sawaya et al11 demonstrated a significant increase in ultrasensitive TnI among patients with HER2-positive breast cancer treated with anthracyclines and trastuzumab. The mean ultrasensitive TnI concentration after completion of anthracycline chemotherapy was higher among women who developed cardiotoxicity (32 vs 17 pg/mL), and an elevated ultrasensitive TnI >30 pg/mL was predictive of subsequent cardiotoxicity (p=0.04).

    There have been multiple reports on the association between TnI elevation and cardiotoxicity with other treatment exposures (eg, sunitinib, sorafenib, lapatinib, etc), but with mixed results.23–25 The 2012 ESMO Clinical Practice Guidelines for cardiovascular toxicity recommend troponin testing at baseline, during and after cancer therapy (Level of evidence III, Grade B).18

    Brain-type natriuretic peptides

    Natriuretic peptides have been studied extensively for their diagnostic and prognostic role in heart failure. Brain-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are standard biomarkers used in clinical practice for the diagnosis and management of heart failure. However, conclusions regarding the role of natriuretic peptides for the prediction and diagnosis of cardiotoxicity remain conflicting. In the largest study of BNP in the cancer setting, Skovgaard et al26 showed that BNP >100 pg/mL was predictive of heart failure (HR 5.5, 95% CI 1.8 to 17.2, p=0.003) in a heterogeneous cohort of 333 patients with cancer with different tumour types and cardiotoxic treatment exposures.

    There is a clear need for additional studies to clarify the role of TnI and BNP assessment during and after cancer therapy. The effectiveness of using biomarkers to detect and identify cardiotoxicity and inform treatment is currently underway (NCT01032278) to assess the role and timing of TnI and BNP testing in patients undergoing anthracycline-based chemotherapy.

    Novel biomarkers

    Many novel biomarkers have been proposed in the monitoring of cardiotoxicity (eg, high sensitivity C-reactive protein, myeloperoxidase, galectin 3, interleukin family molecules including ST2, matrix metalloproteinase and human heart-type fatty acid-binding protein). In a study by Ky et al27 of multiple novel biomarkers in a cohort of 78 patients with breast cancer undergoing doxorubicin and trastuzumab therapy, early increases in TnI and myeloperoxidase (MPO) a neutrophil-derived enzyme of oxidative stress, were associated with an increased risk of first cardiotoxic event.

    Despite many of the above studies demonstrating the promise of biomarkers for their predictive value of cardiotoxicity, many questions remain. These include the timing of biomarker testing, the threshold for each individual biomarker, optimal assay, the incremental clinical value of new biomarkers and the validation of these results in larger independent cohorts. Furthermore, the role and type of biomarkers used for the detection of cancer therapy-associated cardiotoxicity must continue to evolve and adapt as new targeted cancer therapeutics with differing mechanisms of cardiac injury are introduced into clinical practice.

    Multimodality approach

    An approach that integrates multiple circulating biomarkers and/or non-invasive cardiac imaging measures may provide additive value. In a study by Sawaya et al,11 an elevation of ultrasensitive TnI or a decrease in GLS <19% was associated with a sensitivity of 87% for the prediction of trastuzumab cardiotoxicity compared with either parameter alone (74% and 48%, respectively). Similarly, the combination of elevated TnI and MPO levels was shown to identify a group of patients with breast cancer at increased risk for cardiotoxicity than each individual biomarker alone.27 Thus, a combined multimodality approach in selected individuals may provide incremental value in predicting cardiotoxicity and ultimately prove to be the most useful in clinical practice.

    Biomarkers for detection of late cardiotoxicity in cancer survivors

    In cancer survivors, the rationale to perform routine surveillance in the absence of symptoms is that this practice will allow for early identification of LV systolic dysfunction and delay the progression to or onset of clinical heart failure. This issue has been extensively studied among childhood cancer survivors treated with anthracyclines and cardiac radiation, a patient population known to be at increased risk for late-onset cardiotoxicity. The International Late Effects of Childhood Cancer Guideline Harmonization Group was established to resolve differences in guidelines across groups in North America and Europe and proposed an algorithm for cardiomyopathy surveillance that is risk-specific and dependent on treatment exposures.28

    There has been growing interest in the use of STE for the evaluation of subclinical LV dysfunction among childhood cancer survivors. In the St. Jude Lifetime Cohort Study, Armstrong et al performed echocardiography assessment with measurement of 3D LVEF and GLS in 1820 survivors of childhood cancer. Although only 5.8% of survivors had an LVEF <50%, 31.8% had evidence of cardiac dysfunction as defined by a GLS >2 SDs below the mean.29 While certainly quite intriguing, studies are needed to determine the natural history of asymptomatic GLS declines, to examine whether abnormal GLS is predictive of subsequent LVEF declines or clinical heart failure and to study the efficacy of early intervention strategies to improve clinical outcomes.

    There have been few studies on the use of circulating biomarkers for the assessment of late cardiotoxicity in cancer survivors. In a study of 200 childhood cancer survivors previously treated with varying doses of anthracycline chemotherapy, NT-proBNP levels were higher in survivors treated with ≥300 mg/m2 anthracyclines compared with survivors treated with <300 mg/m2 (median 71 vs 37 pg/dL, p=0.01).30 No differences in other biomarkers including BNP, troponin-T, galectin 3 or ST2 were observed. Similar findings of elevated NT-proBNP were reported in two cross-sectional studies of childhood cancer survivors previously treated with anthracyclines.31 Long-term follow-up studies are needed to determine whether NT-pro-BNP levels can identify survivors at increased risk for late cardiotoxicity.

    Fundamental gaps in knowledge and future directions

    Despite the important body of research published to date in cardio-oncology biomarkers, many questions remain unanswered. Which biomarkers provide the greatest prognostic and predictive value, what is the optimal threshold for each biomarker, and what is the optimal timing and frequency of biomarker testing? What is the reproducibility of these measures, and can they be implemented in both academic and community settings? Long-term studies are needed to determine the relationship between biomarker abnormalities and well-defined clinical outcomes, and determine how these markers can better inform the use of cardioprotective strategies. In order to accomplish these goals, a first step could be to leverage the use of imaging and biospecimen repositories from existent studies, and build collaborations among cooperative oncology and cardiology groups. Ultimately, prospective studies and randomised trials are necessary to inform whether the application of biomarkers can improve patient outcomes.

    Conclusions

    Cardiotoxicity remains an important adverse sequela of cancer treatment. The variability in a patient's response to the beneficial and toxic effects of cancer therapy is an increasingly recognised problem within cardio-oncology and has stimulated a close collaborative effort between medical oncologists and cardiologists. Further investigation is needed to identify the best practices for cardiac monitoring prior to, during and after exposure to cardiotoxic therapy. The incorporation of both imaging and circulating biomarkers will likely be a critical component in the development of an evidence-based and risk-specific strategy for cardiac surveillance in order to mitigate the individual patient's risk of cardiotoxicity.

    References

    1. ↵
      1. Von Hoff DD,
      2. Layard MW,
      3. Basa P, et al
      . Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–17. doi:10.7326/0003-4819-91-5-710
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      1. Cheng H,
      2. Force T
      . Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106:21–34. doi:10.1161/CIRCRESAHA.109.206920
      OpenUrlAbstract/FREE Full Text
    3. ↵
      1. Patnaik JL,
      2. Byers T,
      3. DiGuiseppi C, et al
      . Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011;13:R64. doi:10.1186/bcr2901
      OpenUrlCrossRefPubMed
    4. ↵
      1. Shelburne N,
      2. Adhikari B,
      3. Brell J, et al
      . Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst 2014;106:pii:dju232.doi:10.1093/jnci/dju232
      OpenUrlCrossRef
    5. ↵
      1. Yeh ET,
      2. Bickford CL
      . Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231–47. doi:10.1016/j.jacc.2009.02.050
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      1. Shah AM,
      2. Solomon SD
      . Myocardial deformation imaging: current status and future directions. Circulation 2012;125:e244–8. doi:10.1161/CIRCULATIONAHA.111.086348
      OpenUrlFREE Full Text
    7. ↵
      1. Thavendiranathan P,
      2. Grant AD,
      3. Negishi T, et al
      . Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013;61:77–84. doi:10.1016/j.jacc.2012.09.035
      OpenUrlCrossRefPubMedWeb of Science
    8. ↵
      1. Romond EH,
      2. Jeong JH,
      3. Rastogi P, et al
      . Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792–9. doi:10.1200/JCO.2011.40.0010
      OpenUrlAbstract/FREE Full Text
    9. ↵
      1. de Azambuja E,
      2. Procter MJ,
      3. van Veldhuisen DJ, et al
      . Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01). J Clin Oncol 2014;32:2159–65. doi:10.1200/JCO.2013.53.9288
      OpenUrlAbstract/FREE Full Text
    10. ↵
      1. Walker J,
      2. Bhullar N,
      3. Fallah-Rad N, et al
      . Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010;28:3429–36. doi:10.1200/JCO.2009.26.7294
      OpenUrlAbstract/FREE Full Text
    11. ↵
      1. Sawaya H,
      2. Sebag IA,
      3. Plana JC, et al
      . Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596–603. doi:10.1161/CIRCIMAGING.112.973321
      OpenUrlAbstract/FREE Full Text
    12. ↵
      1. Negishi K,
      2. Negishi T,
      3. Hare JL, et al
      . Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493–8. doi:10.1016/j.echo.2013.02.008
      OpenUrlCrossRefPubMed
    13. ↵
      1. Plana JC,
      2. Galderisi M,
      3. Barac A, et al
      . Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of echocardiography and the European Association of cardiovascular imaging. J Am Soc Echocardiogr 2014;27:911–39. doi:10.1016/j.echo.2014.07.012
      OpenUrlCrossRefPubMed
    14. ↵
      1. Jordan JH,
      2. D'Agostino RB Jr.,
      3. Hamilton CA, et al
      . Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2014;7:872–9. doi:10.1161/CIRCIMAGING.114.002217
      OpenUrlAbstract/FREE Full Text
    15. ↵
      1. Thavendiranathan P,
      2. Wintersperger BJ,
      3. Flamm SD, et al
      . Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging 2013;6:1080–91. doi:10.1161/CIRCIMAGING.113.000899
      OpenUrlFREE Full Text
    16. ↵
      1. Neilan TG,
      2. Coelho-Filho OR,
      3. Shah RV, et al
      . Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 2013;111:717–22. doi:10.1016/j.amjcard.2012.11.022
      OpenUrlCrossRefPubMed
    17. ↵
      National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1. 2012. http://www.nccn.org (accessed 30 Jun 2015).
    18. ↵
      1. Curigliano G,
      2. Cardinale D,
      3. Suter T, et al
      . Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 2012;23(Suppl 7):vii155–66. doi:10.1093/annonc/mds293
      OpenUrlAbstract/FREE Full Text
    19. ↵
      1. Reichlin T,
      2. Hochholzer W,
      3. Bassetti S, et al
      . Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858–67. doi:10.1056/NEJMoa0900428
      OpenUrlCrossRefPubMedWeb of Science
    20. ↵
      1. Cardinale D,
      2. Sandri MT,
      3. Martinoni A, et al
      . Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517–22. doi:10.1016/S0735-1097(00)00748-8
      OpenUrlCrossRefPubMedWeb of Science
    21. ↵
      1. Cardinale D,
      2. Sandri MT,
      3. Colombo A, et al
      . Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004;109:2749–54. doi:10.1161/01.CIR.0000130926.51766.CC
      OpenUrlAbstract/FREE Full Text
    22. ↵
      1. Cardinale D,
      2. Colombo A,
      3. Torrisi R, et al
      . Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910–16. doi:10.1200/JCO.2009.27.3615
      OpenUrlAbstract/FREE Full Text
    23. ↵
      1. Schmidinger M,
      2. Zielinski CC,
      3. Vogl UM, et al
      . Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204–12. doi:10.1200/JCO.2007.15.6331
      OpenUrlAbstract/FREE Full Text
    24. ↵
      1. Morris PG,
      2. Chen C,
      3. Steingart R, et al
      . Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 2011;17:3490–9. doi:10.1158/1078-0432.CCR-10-1359
      OpenUrlAbstract/FREE Full Text
    25. ↵
      1. Chu TF,
      2. Rupnick MA,
      3. Kerkela R, et al
      . Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011–p9. doi:10.1016/S0140-6736(07)61865-0
      OpenUrlCrossRefPubMedWeb of Science
    26. ↵
      1. Skovgaard D,
      2. Hasbak P,
      3. Kjaer A
      . BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. PLoS ONE 2014;9:e96736. doi:10.1371/journal.pone.0096736
      OpenUrlCrossRefPubMed
    27. ↵
      1. Ky B,
      2. Putt M,
      3. Sawaya H, et al
      . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63:809–16. doi:10.1016/j.jacc.2013.10.061
      OpenUrlCrossRefPubMedWeb of Science
    28. ↵
      1. Armenian SH,
      2. Hudson MM,
      3. Mulder RL, et al
      . Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16:e123–36. doi:10.1016/S1470-2045(14)70409-7
      OpenUrlCrossRefPubMed
    29. ↵
      1. Armstrong GT,
      2. Joshi VM,
      3. Ness KK, et al
      . Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. J Am Coll Cardiol 2015;65:2511–22. doi:10.1016/j.jacc.2015.04.013
      OpenUrlCrossRefPubMed
    30. ↵
      1. Armenian SH,
      2. Gelehrter SK,
      3. Vase T, et al
      . Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clin Cancer Res 2014;20: 6314–23. doi:10.1158/1078-0432.CCR-13-3490
      OpenUrlAbstract/FREE Full Text
    31. ↵
      1. Mavinkurve-Groothuis AM,
      2. Groot-Loonen J,
      3. Bellersen L, et al
      . Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer 2009;52:631–6. doi:10.1002/pbc.21913
      OpenUrlCrossRefPubMedWeb of Science
      1. Erven K,
      2. Florian A,
      3. Slagmolen P, et al
      . Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy. Int J Radiat Oncol Biol Phys 2013;85:1172–8. doi:10.1016/j.ijrobp.2012.09.022
      OpenUrlCrossRefPubMed
      1. Fallah-Rad N,
      2. Walker JR,
      3. Wassef A, et al
      . The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263–70. doi:10.1016/j.jacc.2010.11.063
      OpenUrlCrossRefPubMedWeb of Science
      1. Sandri MT,
      2. Cardinale D,
      3. Zorzino L, et al
      . Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003;49:248–52. doi:10.1373/49.2.248
      OpenUrlAbstract/FREE Full Text
      1. Romano S,
      2. Fratini S,
      3. Ricevuto E, et al
      . Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011;105:1663–8. doi:10.1038/bjc.2011.439
      OpenUrlCrossRefPubMedWeb of Science
      1. Lipshultz SE,
      2. Miller TL,
      3. Scully RE, et al
      . Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30:1042–9. doi:10.1200/JCO.2010.30.3404
      OpenUrlAbstract/FREE Full Text
      1. Daugaard G,
      2. Lassen U,
      3. Bie P, et al
      . Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005;7:87–93. doi:10.1016/j.ejheart.2004.03.009
      OpenUrlCrossRefPubMedWeb of Science
      1. Dodos F,
      2. Halbsguth T,
      3. Erdmann E, et al
      . Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318–26. doi:10.1007/s00392-007-0633-6
      OpenUrlCrossRefPubMedWeb of Science
      1. Putt M,
      2. Hahn VS,
      3. Januzzi JL, et al
      . Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem 2015;61:1164–72. doi:10.1373/clinchem.2015.241232
      OpenUrlAbstract/FREE Full Text

    Footnotes

    • Contributors BK responded to the call for the manuscript. AFY and BK participated in drafting and revision of the manuscript. All the authors read and approved the final version of the manuscript.

    • Funding BK is supported by NIH NHLBI R01 HL 118018 for this work. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

    • Disclaimer BK has an investigator-initiated research award from Pfizer and has served as a consultant for Roche Diagnostics and Bristol Myers Squibb. AFY has served as a consultant for Bristol Myers Squibb.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; externally peer reviewed.